APGE — Apogee Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.65bn
- $2.13bn
- 33
- 24
- 88
- 46
Annual cashflow statement for Apogee Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -39.8 | -84 | -182 |
| Depreciation | |||
| Non-Cash Items | 13.5 | 3.12 | 12.8 |
| Other Non-Cash Items | |||
| Changes in Working Capital | 9.81 | 6.11 | -2 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -16.4 | -74.8 | -171 |
| Capital Expenditures | — | -0.167 | -1.15 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | -274 | -299 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | — | -274 | -300 |
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 168 | 315 | 495 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 152 | -33.3 | 23.5 |